Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Trial Profile

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2012

At a glance

  • Drugs Bortezomib (Primary) ; Thalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 01 Jun 2012 Results published in the European Journal of Haematology.
    • 08 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top